Kremer B
Chirurgische Universitätsklinik Hamburg-Eppendorf.
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir. 1989:283-5.
According to the European Liver Transplant Registry the percentage of patients selected to receive liver grafts for malignant liver disease decreased from 40% in 1983 to 23% currently. This development is due to disappointing results: 2-year survival rates of about 25-30% have been reported for malignant diseases compared to about 70% for benign diseases. Correlating the stage of the primary tumor and the survival time according to TNM-grading recent publications now show that the T1-3 and N-0 stage are clearly prognostic for long-term survival in contrast to a T-4 or N-1 stage which indicate a limited prognosis for about 90% of patients with HCC and Klatskin carcinoma during the first postoperative year.
根据欧洲肝脏移植登记处的数据,因恶性肝脏疾病而被选中接受肝脏移植的患者比例从1983年的40%降至目前的23%。这种变化是由于令人失望的结果:据报道,恶性疾病的2年生存率约为25%-30%,而良性疾病约为70%。根据TNM分级将原发性肿瘤的分期与生存时间相关联,最近的出版物表明,与T-4或N-1期相比,T1-3和N-0期对长期生存具有明显的预后意义,T-4或N-1期表明约90%的肝癌和肝门部胆管癌患者在术后第一年预后有限。